BR112022016999A2 - Polipeptídeos de ligação modificados para conjugação de fármacos otimizada - Google Patents
Polipeptídeos de ligação modificados para conjugação de fármacos otimizadaInfo
- Publication number
- BR112022016999A2 BR112022016999A2 BR112022016999A BR112022016999A BR112022016999A2 BR 112022016999 A2 BR112022016999 A2 BR 112022016999A2 BR 112022016999 A BR112022016999 A BR 112022016999A BR 112022016999 A BR112022016999 A BR 112022016999A BR 112022016999 A2 BR112022016999 A2 BR 112022016999A2
- Authority
- BR
- Brazil
- Prior art keywords
- modified
- amino acid
- acid residue
- reactive amino
- kabat
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
POLIPEPTÍDEOS DE LIGAÇÃO MODIFICADOS PARA CONJUGAÇÃO DE FÁRMACOS OTIMIZADA. Anticorpos modificados que são estáveis e podem ser conjugados a um ligante ou fármaco em uma relação ligante/fármaco para anticorpo acima de 3, tornando esses conjugados adequados para o tratamento de uma variedade de indicações, são fornecidos. Métodos de produção desses anticorpos modificados também são fornecidos. Em uma primeira modalidade, o anticorpo compreende um primeiro resíduo de aminoácido reativo modificado na posição 274 de acordo com a numeração do índice EU de Kabat e um segundo resíduo de aminoácido reativo modificado na posição 339, 360, 384, 385, 422 e/ou 440. Em uma segunda modalidade, o anticorpo compreende um primeiro resíduo de aminoácido reativo modificado na posição 339 de acordo com a numeração do índice EU de Kabat e um segundo resíduo de aminoácido reativo modificado na posição 290, 360, 384, 385, 422 e /ou 440. Em uma terceira modalidade, o anticorpo compreende um primeiro resíduo de aminoácido reativo modificado na posição 118 de acordo com a numeração do índice EU de Kabat e um segundo resíduo de aminoácido reativo modificado na posição 274, 339, 384, 385, 422 e/ou 440. Em uma quarta modalidade, o anticorpo compreende um primeiro resíduo de aminoácido reativo modificado na posição 384 de acordo com a numeração do índice EU de Kabat e um segundo resíduo de aminoácido reativo modificado na posição 118, 274, 290 e/ou 339. Em uma modalidade preferida, o resíduo de aminoácido reativo modificado é cisteína.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062982943P | 2020-02-28 | 2020-02-28 | |
PCT/US2021/019958 WO2021174034A1 (en) | 2020-02-28 | 2021-02-26 | Modified binding polypeptides for optimized drug conjugation |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022016999A2 true BR112022016999A2 (pt) | 2022-10-25 |
Family
ID=75143734
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022016999A BR112022016999A2 (pt) | 2020-02-28 | 2021-02-26 | Polipeptídeos de ligação modificados para conjugação de fármacos otimizada |
Country Status (14)
Country | Link |
---|---|
US (2) | US11879004B2 (pt) |
EP (1) | EP4110404A1 (pt) |
JP (1) | JP2023516952A (pt) |
KR (1) | KR20220148235A (pt) |
CN (1) | CN115515643A (pt) |
AR (1) | AR121462A1 (pt) |
AU (1) | AU2021225962A1 (pt) |
BR (1) | BR112022016999A2 (pt) |
CA (1) | CA3169521A1 (pt) |
CO (1) | CO2022013737A2 (pt) |
IL (1) | IL295590A (pt) |
MX (1) | MX2022010538A (pt) |
TW (1) | TW202200209A (pt) |
WO (1) | WO2021174034A1 (pt) |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
EP0627932B1 (en) | 1992-11-04 | 2002-05-08 | City Of Hope | Antibody construct |
EP0752248B1 (en) | 1992-11-13 | 2000-09-27 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
EP0770628B9 (en) | 1994-07-13 | 2007-02-28 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin-8 |
GB9422383D0 (en) | 1994-11-05 | 1995-01-04 | Wellcome Found | Antibodies |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
WO1997014719A1 (en) | 1995-10-16 | 1997-04-24 | Unilever N.V. | A bifunctional or bivalent antibody fragment analogue |
GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
AU3968897A (en) | 1996-08-02 | 1998-02-25 | Bristol-Myers Squibb Company | A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis |
WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
DK1068241T3 (da) | 1998-04-02 | 2008-02-04 | Genentech Inc | Antistofvarianter og fragmenter deraf |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
EP1006183A1 (en) | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Recombinant soluble Fc receptors |
ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
EP1294904A1 (en) | 2000-06-30 | 2003-03-26 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Heterodimeric fusion proteins |
GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
ES2649037T3 (es) | 2000-12-12 | 2018-01-09 | Medimmune, Llc | Moléculas con semividas prolongadas, composiciones y usos de las mismas |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
WO2003074679A2 (en) * | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
US20040018557A1 (en) | 2002-03-01 | 2004-01-29 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
CA2495251C (en) | 2002-08-14 | 2018-03-06 | Macrogenics, Inc. | Fc.gamma.riib-specific antibodies and methods of use thereof |
DK2345671T3 (en) | 2002-09-27 | 2016-02-15 | Xencor Inc | Optimized Fc variants and methods for their formation |
AU2003286467B2 (en) | 2002-10-15 | 2009-10-01 | Abbvie Biotherapeutics Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
JP2006524039A (ja) | 2003-01-09 | 2006-10-26 | マクロジェニクス,インコーポレーテッド | 変異型Fc領域を含む抗体の同定および作製ならびにその利用法 |
GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
EP1697415A1 (en) | 2003-11-12 | 2006-09-06 | Biogen Idec MA Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
EP1697520A2 (en) | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
US20080089892A1 (en) | 2004-01-12 | 2008-04-17 | Eli Lilly And Co. | Fc Region Variants |
EP1737890A2 (en) | 2004-03-24 | 2007-01-03 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
WO2006085967A2 (en) | 2004-07-09 | 2006-08-17 | Xencor, Inc. | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
EP2471813B1 (en) | 2004-07-15 | 2014-12-31 | Xencor, Inc. | Optimized Fc variants |
NZ580115A (en) | 2004-09-23 | 2010-10-29 | Genentech Inc | Cysteine engineered antibody light chains and conjugates |
WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
EP1896503B1 (en) | 2005-05-31 | 2014-10-29 | Board of Regents, The University of Texas System | IgG1 ANTIBODIES WITH MUTATED Fc PORTION FOR INCREASED BINDING TO FcRn RECEPTOR AND USES TEHEREOF |
WO2008020827A2 (en) * | 2005-08-01 | 2008-02-21 | Biogen Idec Ma Inc. | Altered polypeptides, immunoconjugates thereof, and methods related thereto |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
US7833260B2 (en) | 2006-07-20 | 2010-11-16 | Orbusneich Medical, Inc. | Bioabsorbable polymeric medical device |
SI2195023T1 (en) | 2007-08-29 | 2018-07-31 | Sanofi | Humanized anti-CXCR5 antibodies, their derivatives and their uses |
EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
TWI743461B (zh) | 2011-03-28 | 2021-10-21 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
PT2953976T (pt) * | 2013-02-08 | 2021-06-23 | Novartis Ag | Sítios específicos de modificação de anticorpos para preparar imunoconjugados |
MX2016011627A (es) * | 2014-03-12 | 2016-11-29 | Novartis Ag | Sitios especificos para modificar anticuerpos con el fin de hacer inmunoconjugados. |
EP3129067B1 (en) | 2014-03-19 | 2023-01-04 | Genzyme Corporation | Site-specific glycoengineering of targeting moieties |
ES2719584T3 (es) * | 2014-04-11 | 2019-07-11 | Medimmune Llc | Compuestos conjugados que comprenden anticuerpos modificados por ingeniería genética con cisteína |
US11364303B2 (en) | 2017-09-29 | 2022-06-21 | Pfizer Inc. | Cysteine engineered antibody drug conjugates |
CN113301925A (zh) | 2018-12-19 | 2021-08-24 | 小利兰·斯坦福大学理事会 | 用于溶酶体靶向的双官能分子以及相关的组合物和方法 |
-
2021
- 2021-02-26 CN CN202180017297.0A patent/CN115515643A/zh active Pending
- 2021-02-26 WO PCT/US2021/019958 patent/WO2021174034A1/en active Application Filing
- 2021-02-26 EP EP21713806.4A patent/EP4110404A1/en active Pending
- 2021-02-26 AU AU2021225962A patent/AU2021225962A1/en active Pending
- 2021-02-26 MX MX2022010538A patent/MX2022010538A/es unknown
- 2021-02-26 BR BR112022016999A patent/BR112022016999A2/pt unknown
- 2021-02-26 TW TW110107069A patent/TW202200209A/zh unknown
- 2021-02-26 KR KR1020227033354A patent/KR20220148235A/ko active Search and Examination
- 2021-02-26 US US17/187,039 patent/US11879004B2/en active Active
- 2021-02-26 AR ARP210100525A patent/AR121462A1/es unknown
- 2021-02-26 CA CA3169521A patent/CA3169521A1/en active Pending
- 2021-02-26 JP JP2022551617A patent/JP2023516952A/ja active Pending
- 2021-02-26 IL IL295590A patent/IL295590A/en unknown
-
2022
- 2022-09-26 CO CONC2022/0013737A patent/CO2022013737A2/es unknown
-
2023
- 2023-04-19 US US18/303,353 patent/US20230391849A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2021174034A1 (en) | 2021-09-02 |
MX2022010538A (es) | 2022-09-21 |
EP4110404A1 (en) | 2023-01-04 |
CO2022013737A2 (es) | 2022-10-21 |
US11879004B2 (en) | 2024-01-23 |
US20230391849A1 (en) | 2023-12-07 |
CA3169521A1 (en) | 2021-09-02 |
IL295590A (en) | 2022-10-01 |
TW202200209A (zh) | 2022-01-01 |
JP2023516952A (ja) | 2023-04-21 |
US20210292391A1 (en) | 2021-09-23 |
CN115515643A (zh) | 2022-12-23 |
AR121462A1 (es) | 2022-06-08 |
KR20220148235A (ko) | 2022-11-04 |
AU2021225962A1 (en) | 2022-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2010001209A1 (es) | Anticuerpos monoclonales aislados que preferentemente se unen al polipeptido ca 125/o772p asociado a celulas en relacion al polipeptido ca 125/o772p soluble; hibridoma; acido nucleico que los codifica; composicion farmaceutica; kit polipeptido de fusion; y su uso para preparar un medicamento para tratar un desorden celular proliferativo (divisional de sol. n° 2086-03). | |
PL1639011T3 (pl) | Pegilowane przeciwciała jednodomenowe (dAb) | |
FR2437213A1 (fr) | Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation | |
AR069903A1 (es) | Conjugado anticuerpo- molecula asociada dirigidos a la proteina tirosina quinasa 7 (ptk 7), composicion farmaceutica que lo comprende, acido nucleico, factor de expresion y celula huesped relacionados y su uso para preparar un medicamento util para el tratamiento o prevencion de cancer | |
EA200700213A1 (ru) | Терапевтические композиции с нейротоксином ботулина | |
ATE27915T1 (de) | Kovalente konjugate,die ein enzym und einen antikoerper verbinden und medikamentoese zubereitungen,die diese konjugate enthalten. | |
DE69738868D1 (de) | Odieren, und deren verwendung zur vorbeugung und zum nachweis von krebs | |
BR0209689A (pt) | Uso de fragmento de hmg como agente anti-inflamatório | |
MXPA05007823A (es) | Composicion y tratamiento de enfermedades desmielizantes y paralisis por administracion de agentes remielinizantes. | |
BRPI0418766B8 (pt) | anticorpo ou seu fragmento, vetor, composição farmacêutica, ensaio e método para detectar a presença de proteína steap-1, bem como método para distribuir um agente citotóxico ou um agente de diagnóstico | |
EA200600469A1 (ru) | Клетки, продуцирующие композиции антител | |
AR067995A1 (es) | Acoplamiento en sitio especifico de farmacos u otros agentes a anticuerpos disenados con extensiones c-terminales | |
ECSP055635A (es) | Agentes citotoxicos que contienen taxanos potentes novedosos y su uso terapeutico | |
ATE112687T1 (de) | Mutanten des hiv-1 hüllproteins mit fehlenden hypervariabelen domänen. | |
KR870005648A (ko) | 슈도모나스 이루지노사 항원형에 대한 교차면역 반응성 및 교차보호성 단일분지계 항체 | |
BR0207151A (pt) | Moléculas de aglutinação terapêuticas | |
KR900013986A (ko) | 종양-관련항원에 대한 모노클로날 항체(MAb_s), 이의 제조방법 및 용도 | |
BR112022006817A2 (pt) | Anticorpos direcionados a flt3 e uso dos mesmos | |
CO2021016183A2 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-angptl3 | |
BR112022016999A2 (pt) | Polipeptídeos de ligação modificados para conjugação de fármacos otimizada | |
BR0116122A (pt) | Peptìdeos e/ou proteìnas bem como seu uso para preparar uma composição farmacêutica, terapêutica e/ou preventiva | |
BRPI0910509B8 (pt) | uso do anticorpo, anticorpo e composição farmacêutica | |
ES2085329T3 (es) | Agente anticanceroso proteico. | |
DE3688137D1 (de) | Ricin-antikoerper-konjugate. | |
BR112023019698A2 (pt) | Construtos de anticorpo modificados por cisteína, conjugados e métodos de uso |